Lupin Generics Company Intelligence Report

Date: January 22, 2011
Pages: 16
Price:
US$ 340.00
License [?]:
Publisher: Espicom Business Intelligence
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: L98F2357448EN
Leaflet:

Download PDF Leaflet

Lupin Generics Company Intelligence Report
Lupin's roots stretch back to 1968, with its formulations commercialised in 1976. In 1981, Lupin began ethambutol production, becoming one of the largest producers in
the world. In 1991, Lupin began cephalosporin production.

Lupin's first ANDA to be approved by the US FDA was cefuorxime axetil, which gained approval in 2003. In 2004, Lupin introduced its first brand to the US: Suprax, a
cefixime product that had previously been marketed by Wyeth until March 2003.

The firm's products are available in nearly 70 countries, with its overseas business accounting for around 65% of total revenues.

For the year ended 31st March 2010, Lupin announced consolidated sales worth Rs47,678.4 million (US$1,006.5 million). This was an increase of 24.7% over the prior
year. Net profit rose by 35.9% to Rs6,816.3 million (US$143.9 million).

EXECUTIVE SUMMARY

INTRODUCTION

PRODUCTS

Lupin ANDA Approvals, January 2002 – September 2010
Recent Product Approvals
Desloratadine (US)
Cefixime (US)
Losartan and losartan / hydrochlorothiazide (US)
Famotidine (US)
Lamotrigine (US)
Imipramine (US)
Eszopiclone (US, tentative)
Sodium hyaluronate (India)
Amlodipine / benazepril (US)
Perindopril (US)
Memantine (US, tentative)

FINANCIAL RESULTS

Latest Quarterly Results, Q210/11
Lupin: consolidated quarterly results, in Rs millions
Lupin: consolidated quarterly results, in US$ millions
Latest Yearly Results, FY2009/10
Lupin: Consolidated Fiscal Year Results, in Rs millions
Lupin: Consolidated Fiscal Year Results, in US$ millions
Segment breakdown
United States
Europe
India
AAMLA
APIs

MAJOR DEVELOPMENTS

Lupin's Mandideep facility gains FDA approval
Mergers, acquisitions and agreements
Salix acquires US rights to Lupin's bioadhesive technology for rifaximin product
Lupin acquires US rights to branded fenofibrate capsules
Litigation
Lupin loses levofloxacin patent challenge
Warner Chilcott settles oral contraceptive litigation with Lupin
Forest / Merz settle memantine litigation
Gilead files ranolazine patent lawsuit against Lupin
Depomed files lawsuit against Lupin

CONTACT DETAILS
Skip to top


Apotex Generics Company Intelligence Report US$ 340.00 Jan, 2011 · 20 pages
Krka Generics Company Intelligence Report US$ 340.00 Jan, 2011 · 16 pages
Sandoz Generics Company Intelligence Report US$ 340.00 Jan, 2011 · 30 pages
Zydus Cadila Generics Company Intelligence Report US$ 340.00 Jan, 2011 · 12 pages

Ask Your Question

Lupin Generics Company Intelligence Report
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: